The company was founded in 20161. PathAI is based in Boston, United States, and specializes in developing an artificial intelligence-powered research platform intended to improve the accuracy and efficiency of cancer diagnosis and treatment. As of December 2023, the company has raised significant funding but remains privately held.
PathAI puts AI technology to work aiding pathologists in accurately diagnosing and treating patients. PathAI focuses on cutting out the subjectivity that can lead to errors and negative outcomes for patients. The company’s investors have included Kaiser Permanente and Merck.